Please find enclosed the Audited Standalone and Consolidated Results for the quarter and year ended March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GKB Ophthalmics Ltd has filed its audited standalone and consolidated financial results for Q4 FY25 and the full year ended March 31, 2025, approved by the Board on May 30, 2025. On a standalone basis, the company appears to have reported a net loss for FY25, with negative earnings per share, and operating cash flow turned negative for the year. Cash and cash equivalents fell sharply from about Rs. 3,114 lakhs to Rs. 1,260 lakhs on a standalone basis, indicating a meaningful liquidity drawdown. Consolidated results showed only a marginal loss, with subsidiary LeLino-The Lens Company, step-down subsidiaries (Prescript Optical Products LLC and Imtrex Ophthalmic Products Pty Ltd) and associate GKB Vision FZC included in the group reporting. Auditor MSKA & Associates issued an unqualified (clean) opinion on both the standalone and consolidated statements, with no going concern qualification or emphasis of matter flagged. The company also disclosed tracking of about Rs. 1,512 lakhs raised via a preferential issue, earmarked for growth plans (organic and inorganic) and capacity expansion.
Negative: standalone loss, weakening cash balance, and negative operating cash flow are concerns for shareholders and may weigh on the stock. The clean audit opinion and continued capacity expansion plans provide some offset, but investors should watch for traction in capacity utilisation and improvement in subsidiary profitability.